ATE249830T1 - Die verwendung von r (+)- g(a)-(2,3- dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol zur behandlung von obstruktive schlafapnoe - Google Patents

Die verwendung von r (+)- g(a)-(2,3- dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol zur behandlung von obstruktive schlafapnoe

Info

Publication number: ATE249830T1
Authority: AT; Austria
Prior art keywords: piperidinemethanol; dimethoxyphenyl; fluorophenyl; treatment; ethyl
Prior art date: 1998-08-28

Application number

AT99936000T

Other languages

English (en)

Inventor

Cesare Mondadori

Stephen M Sorensen

Janice M Hitchcock

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-28

Filing date

1999-07-29

Publication date

2003-10-15

1999-07-29 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2003-10-15 Application granted granted Critical

2003-10-15 Publication of ATE249830T1 publication Critical patent/ATE249830T1/de

Links

208000001797 obstructive sleep apnea Diseases 0.000 title 1
150000003839 salts Chemical class 0.000 abstract 1
208000019116 sleep disease Diseases 0.000 abstract 1
208000020685 sleep-wake disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Anesthesiology (AREA)
Hydrogenated Pyridines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT99936000T 1998-08-28 1999-07-29 Die verwendung von r (+)- g(a)-(2,3- dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol zur behandlung von obstruktive schlafapnoe ATE249830T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14313598A	1998-08-28	1998-08-28
PCT/US1999/017331 WO2000012090A1 (en)	1998-08-28	1999-07-29	THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

Publications (1)

Publication Number	Publication Date
ATE249830T1 true ATE249830T1 (de)	2003-10-15

Family

ID=22502745

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99936000T ATE249830T1 (de)	1998-08-28	1999-07-29	Die verwendung von r (+)- g(a)-(2,3- dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol zur behandlung von obstruktive schlafapnoe

Country Status (32)

Country	Link
EP (2)	EP1105132B1 (de)
JP (1)	JP2002523460A (de)
KR (3)	KR100682799B1 (de)
CN (1)	CN1127954C (de)
AT (1)	ATE249830T1 (de)
AU (1)	AU764604B2 (de)
BG (2)	BG109953A (de)
BR (1)	BR9913242A (de)
CA (2)	CA2341891C (de)
CZ (1)	CZ300781B6 (de)
DE (2)	DE69911436T2 (de)
DK (1)	DK1105132T3 (de)
EA (1)	EA003791B1 (de)
EE (1)	EE04951B1 (de)
ES (1)	ES2204146T3 (de)
HK (1)	HK1040907B (de)
HR (2)	HRP20010140A2 (de)
HU (1)	HUP0202145A3 (de)
ID (1)	ID29601A (de)
IL (2)	IL141603A0 (de)
ME (1)	MEP20308A (de)
MX (1)	MXPA01002026A (de)
NO (2)	NO20010984L (de)
NZ (1)	NZ510083A (de)
PL (1)	PL195022B1 (de)
PT (1)	PT1105132E (de)
SK (1)	SK284858B6 (de)
TR (1)	TR200100670T2 (de)
TW (1)	TWI233802B (de)
UA (1)	UA74773C2 (de)
WO (1)	WO2000012090A1 (de)
ZA (1)	ZA200101466B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020099076A1 (en)	2000-05-25	2002-07-25	Richard Scheyer D.	Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
DK1534391T3 (da)	2002-07-19	2007-06-11	Biovitrum Ab	Nye piperazinyl-pyrazinonderivater til behandling af 5-HT2A-recptor-relaterede forstyrrelser

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5169096A (en)	1985-07-02	1992-12-08	Merrell Dow Pharmaceuticals Inc.	N-aralkyl-piperidine-methanol derivatives
US4877798A (en) *	1987-11-23	1989-10-31	Merrell Dow Pharmaceuticals Inc.	Treatment of fibromyalgia
ATE102482T1 (de) *	1988-01-21	1994-03-15	Merrell Dow Pharma	Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit.
WO1991018602A1 (en)	1990-06-01	1991-12-12	Merrell Dow Pharmaceuticals Inc.	(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL
JPH05134149A (ja) *	1991-11-08	1993-05-28	Nippondenso Co Ltd	光半導体モジユール
US5618824A (en)	1994-03-09	1997-04-08	Merrell Pharmaceuticals Inc.	Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (de) *	1996-03-21	1997-09-24	Merrell Pharmaceuticals Inc.	Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen
US9702597B1 (en)	2016-02-18	2017-07-11	King Fahd University Of Petroleum And Minerals	System and method for preventing absorbent crystallization in a continuously operating solar-powered absorption cooling system with hybrid storage

1999
- 1999-07-29 HR HR20010140A patent/HRP20010140A2/hr not_active Application Discontinuation
- 1999-07-29 NZ NZ510083A patent/NZ510083A/en active IP Right Revival
- 1999-07-29 UA UA2001032044A patent/UA74773C2/uk unknown
- 1999-07-29 SK SK269-2001A patent/SK284858B6/sk not_active IP Right Cessation
- 1999-07-29 HR HR20080389A patent/HRP20080389A2/xx not_active Application Discontinuation
- 1999-07-29 EP EP99936000A patent/EP1105132B1/de not_active Expired - Lifetime
- 1999-07-29 PL PL99346342A patent/PL195022B1/pl not_active IP Right Cessation
- 1999-07-29 WO PCT/US1999/017331 patent/WO2000012090A1/en not_active Ceased
- 1999-07-29 DK DK99936000T patent/DK1105132T3/da active
- 1999-07-29 EE EEP200100122A patent/EE04951B1/xx not_active IP Right Cessation
- 1999-07-29 DE DE69911436T patent/DE69911436T2/de not_active Expired - Fee Related
- 1999-07-29 PT PT99936000T patent/PT1105132E/pt unknown
- 1999-07-29 KR KR1020017002503A patent/KR100682799B1/ko not_active Expired - Fee Related
- 1999-07-29 MX MXPA01002026A patent/MXPA01002026A/es not_active IP Right Cessation
- 1999-07-29 HK HK02100699.2A patent/HK1040907B/zh not_active IP Right Cessation
- 1999-07-29 ME MEP-203/08A patent/MEP20308A/xx unknown
- 1999-07-29 DE DE69941134T patent/DE69941134D1/de not_active Expired - Fee Related
- 1999-07-29 HU HU0202145A patent/HUP0202145A3/hu unknown
- 1999-07-29 IL IL14160399A patent/IL141603A0/xx active IP Right Grant
- 1999-07-29 EA EA200100201A patent/EA003791B1/ru not_active IP Right Cessation
- 1999-07-29 ES ES99936000T patent/ES2204146T3/es not_active Expired - Lifetime
- 1999-07-29 AU AU51359/99A patent/AU764604B2/en not_active Ceased
- 1999-07-29 CZ CZ20010726A patent/CZ300781B6/cs not_active IP Right Cessation
- 1999-07-29 JP JP2000567207A patent/JP2002523460A/ja active Pending
- 1999-07-29 BR BR9913242-7A patent/BR9913242A/pt not_active Application Discontinuation
- 1999-07-29 TR TR2001/00670T patent/TR200100670T2/xx unknown
- 1999-07-29 AT AT99936000T patent/ATE249830T1/de not_active IP Right Cessation
- 1999-07-29 CA CA002341891A patent/CA2341891C/en not_active Expired - Fee Related
- 1999-07-29 KR KR1020067008591A patent/KR100735513B1/ko not_active Expired - Fee Related
- 1999-07-29 EP EP03013686A patent/EP1362589B1/de not_active Expired - Lifetime
- 1999-07-29 KR KR1020067003420A patent/KR100764532B1/ko not_active Expired - Fee Related
- 1999-07-29 CN CN99810423A patent/CN1127954C/zh not_active Expired - Fee Related
- 1999-07-29 CA CA002629396A patent/CA2629396A1/en not_active Abandoned
- 1999-07-29 ID IDW20010489A patent/ID29601A/id unknown
- 1999-08-23 TW TW088114405A patent/TWI233802B/zh not_active IP Right Cessation
2001
- 2001-02-21 ZA ZA200101466A patent/ZA200101466B/en unknown
- 2001-02-22 IL IL141603A patent/IL141603A/en not_active IP Right Cessation
- 2001-02-23 BG BG101099A patent/BG109953A/bg unknown
- 2001-02-23 BG BG105289A patent/BG65416B1/bg unknown
- 2001-02-27 NO NO20010984A patent/NO20010984L/no not_active Application Discontinuation
2009
- 2009-03-13 NO NO20091111A patent/NO20091111L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2341891A1 (en)	2000-03-09
NZ510083A (en)	2003-08-29
HRP20080389A2 (hr)	2008-11-30
TR200100670T2 (tr)	2001-06-21
TWI233802B (en)	2005-06-11
NO20091111L (no)	2001-04-25
BR9913242A (pt)	2001-05-15
CZ2001726A3 (en)	2001-06-13
CA2629396A1 (en)	2000-03-09
EP1362589A1 (de)	2003-11-19
DE69911436D1 (de)	2003-10-23
HRP20010140A2 (en)	2002-02-28
DK1105132T3 (da)	2003-11-24
CA2341891C (en)	2009-05-12
PT1105132E (pt)	2004-02-27
HK1040907B (zh)	2004-04-02
JP2002523460A (ja)	2002-07-30
EP1105132A1 (de)	2001-06-13
EP1105132B1 (de)	2003-09-17
KR100735513B1 (ko)	2007-07-06
CN1127954C (zh)	2003-11-19
AU764604B2 (en)	2003-08-21
HK1040907A1 (en)	2002-06-28
KR20060057029A (ko)	2006-05-25
IL141603A (en)	2006-08-20
ZA200101466B (en)	2002-05-21
CZ300781B6 (cs)	2009-08-12
KR100682799B1 (ko)	2007-02-15
NO20010984L (no)	2001-04-25
KR20010073026A (ko)	2001-07-31
BG65416B1 (bg)	2008-07-31
IL141603A0 (en)	2002-03-10
MEP20308A (en)	2010-06-10
AU5135999A (en)	2000-03-21
PL195022B1 (pl)	2007-08-31
NO20010984D0 (no)	2001-02-27
PL346342A1 (en)	2002-02-11
SK284858B6 (sk)	2006-01-05
MXPA01002026A (es)	2003-03-27
ES2204146T3 (es)	2004-04-16
DE69911436T2 (de)	2004-07-01
EE200100122A (et)	2002-06-17
KR20060023197A (ko)	2006-03-13
ID29601A (id)	2001-09-06
SK2692001A3 (en)	2001-07-10
HUP0202145A2 (hu)	2003-01-28
BG105289A (en)	2001-11-30
DE69941134D1 (de)	2009-08-27
EA003791B1 (ru)	2003-10-30
HUP0202145A3 (en)	2003-02-28
CN1315861A (zh)	2001-10-03
BG109953A (en)	2007-12-28
KR100764532B1 (ko)	2007-10-09
WO2000012090A1 (en)	2000-03-09
EE04951B1 (et)	2008-02-15
UA74773C2 (en)	2006-02-15
EP1362589B1 (de)	2009-07-15
EA200100201A1 (ru)	2001-08-27

Legal Events

Date

Code

Title

Description

2004-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1105132

Country of ref document: EP

2010-04-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69616376D1 (de)	2001-11-29	Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE60031396D1 (de)	2006-11-30	Zubereitung zur behandlung von einer neurologischen erkrankung
DE602004020263D1 (de)	2009-05-07	Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
DE69814394D1 (de)	2003-06-12	Verwendung von levobupivacain
DE69800859D1 (de)	2001-07-05	Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
MY111623A (en)	2000-09-27	Neuroprotective compounds
ATE332688T1 (de)	2006-08-15	Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE234617T1 (de)	2003-04-15	Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
DE69836783D1 (de)	2007-02-15	Methode zur Behandlung des Tourette-Syndroms
JO3446B1 (ar)	2020-07-05	طريقة لمعالجة الأرق الأولي
DE69431199D1 (de)	2002-09-26	Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE69713571D1 (de)	2002-08-01	Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen
DE69733169D1 (de)	2005-06-09	Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
ATE294584T1 (de)	2005-05-15	Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
MY134059A (en)	2007-11-30	Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
DE69911436D1 (de)	2003-10-23	Die verwendung von r (+)- g(a)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol zur behandlung von obstruktive schlafapnoe
DE69906701D1 (de)	2003-05-15	Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
ATE295731T1 (de)	2005-06-15	Olanzapine zur behandlung von drogenmissbrauch
DE69800906D1 (de)	2001-07-19	Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ATE228126T1 (de)	2002-12-15	2- 4-(4-(4,5-dichlor-2-methylimidazol-1- yl)butyl)piperazin-1-yl -5-fluorpyrimidin, seine herstellung und therapeutische verwendung